NASDAQ:CASI CASI Pharmaceuticals (CASI) Stock Price, News & Analysis $2.01 -0.08 (-3.83%) Closing price 03:59 PM EasternExtended Trading$2.06 +0.06 (+2.74%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CASI Pharmaceuticals Stock (NASDAQ:CASI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CASI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.01▼$2.1150-Day Range$1.22▼$2.4752-Week Range$1.09▼$7.50Volume286,475 shsAverage Volume62,081 shsMarket Capitalization$24.72 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company Overview CASI Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company leverages a combination of small‐molecule targeted drugs and biologics to address high‐unmet medical needs in cancer and autoimmune diseases. CASI’s R&D efforts emphasize the discovery and advancement of compounds that modulate key signaling pathways, with a goal of delivering differentiated treatment options to patients worldwide. The company’s lead clinical candidate is famitinib, a multi‐targeted tyrosine kinase inhibitor that has been evaluated in various solid tumors, including gastric, breast and renal cancers. In addition to famitinib, CASI is advancing an immuno-oncology portfolio that includes checkpoint inhibitors and novel immune modulators designed to enhance antitumor responses. Preclinical programs focus on next‐generation molecules with potential applications in both oncology and inflammatory disorders, building on the company’s proprietary discovery platform. Founded by a team of biotech entrepreneurs and scientists, CASI Pharmaceuticals is headquartered in Beijing, with research and development operations in Shanghai and a presence in North America to support global clinical activities. The company has established strategic partnerships with academic institutions and contract research organizations to accelerate its clinical trials and expand its pipeline. CASI’s leadership team comprises industry veterans with extensive experience in drug development and regulatory affairs, guiding the company through key milestones as it pursues regulatory approvals and commercial readiness.AI Generated. May Contain Errors. Read More CASI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreCASI MarketRank™: CASI Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 281st out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingCASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialCASI Pharmaceuticals has a consensus price target of $4.00, representing about 99.0% upside from its current price of $2.01.Amount of Analyst CoverageCASI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about CASI Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCASI Pharmaceuticals has a P/B Ratio of 16.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CASI Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.23% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CASI Pharmaceuticals has recently increased by 12.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCASI Pharmaceuticals does not currently pay a dividend.Dividend GrowthCASI Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.50 Percentage of Shares Shorted9.23% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CASI Pharmaceuticals has recently increased by 12.78%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.95 News SentimentCASI Pharmaceuticals has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CASI Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest3 people have searched for CASI on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.23% of the stock of CASI Pharmaceuticals is held by institutions.Read more about CASI Pharmaceuticals' insider trading history. Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CASI Stock News HeadlinesComparing CASI Pharmaceuticals (NASDAQ:CASI) & Enanta Pharmaceuticals (NASDAQ:ENTA)September 15 at 4:05 AM | americanbankingnews.comCASI announces SMC recommendation to escalate CID-103 dose to next cohortSeptember 8, 2025 | msn.comCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really investing in this coin.September 16 at 2:00 AM | Crypto 101 Media (Ad)HC Wainwright Issues Optimistic Estimate for CASI EarningsSeptember 7, 2025 | americanbankingnews.comCASI Pharmaceuticals (NASDAQ:CASI) Receives "Buy" Rating from HC WainwrightSeptember 5, 2025 | americanbankingnews.comWhat is HC Wainwright's Forecast for CASI Q1 Earnings?September 5, 2025 | americanbankingnews.comCASI Pharmaceuticals stock soars after FDA clearance for transplant drugAugust 5, 2025 | investing.comCASI Pharmaceuticals Stock Surges 12.4% Following FDA Clearance for Transplant DrugAugust 5, 2025 | msn.comSee More Headlines CASI Stock Analysis - Frequently Asked Questions How have CASI shares performed this year? CASI Pharmaceuticals' stock was trading at $2.83 at the start of the year. Since then, CASI stock has decreased by 29.0% and is now trading at $2.01. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals Inc. (NASDAQ:CASI) issued its earnings results on Friday, August, 29th. The biotechnology company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.39. The biotechnology company earned $4.18 million during the quarter, compared to analyst estimates of $6.28 million. CASI Pharmaceuticals had a negative net margin of 148.55% and a negative trailing twelve-month return on equity of 972.55%. When did CASI Pharmaceuticals' stock split? Shares of CASI Pharmaceuticals reverse split on the morning of Wednesday, June 1st 2022.The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are CASI Pharmaceuticals' major shareholders? Top institutional investors of CASI Pharmaceuticals include Foresite Capital Management VI LLC (6.40%). View institutional ownership trends. How do I buy shares of CASI Pharmaceuticals? Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/29/2025Today9/16/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CASI CIK895051 Webwww.casipharmaceuticals.com Phone861065086063Fax301-315-2437Employees180Year Founded1991Price Target and Rating Average Price Target for CASI Pharmaceuticals$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+95.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($2.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.26 million Net Margins-148.55% Pretax Margin-137.90% Return on Equity-972.55% Return on Assets-99.07% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.39 Sales & Book Value Annual Sales$28.54 million Price / Sales0.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book17.04Miscellaneous Outstanding Shares12,300,000Free Float9,687,000Market Cap$25.15 million OptionableOptionable Beta0.77 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:CASI) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.